Gefitinib companion diagnostic - AstraZeneca/QIAGENAlternative Names: Circulating tumour DNA test - AstraZeneca/QIAGEN; Liquid biopsy based gefitinib companion diagnostic - AstraZeneca/QIAGEN; therascreen EGFR RGQ PCR Kit (gefitinib)
Latest Information Update: 15 Jul 2015
At a glance
- Originator QIAGEN
- Developer AstraZeneca; QIAGEN
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Non-small cell lung cancer